Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
RDUS has made a solid floor about $18 all year, above the 200 sma. Volume decreased on the pullback in April. RDUS actually has sales ~$250 million, and a 30% growth rate forecast.
This could come tumbling down. Going back above the 50 sma would indicate possible break of downtrend.
